Pharming Group Faces Regulatory Hurdle as FDA Seeks More Data for Pediatric APDS Drug
Shares of Pharming Group (ENXTAM:PHARM) came under pressure after the U.S. FDA issued a Complete Response Letter for its supplemental filing of Joenja in children with APDS. While the short-term sentiment turned negative, the company's longer-term growth trajectory and valuation gap present a complex picture for investors.